About Sarepta Therapeutics, Inc. - Common Stock (SRPT)
Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders. The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases. Read More
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) compared to placebo in 225 patients, ages 6-13 years old, with Duchenne muscular dystrophy (Duchenne) amenable to exon 45 or 53 skipping.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2025 financial results and recent corporate developments.
New York, NY – October 23, 2025 – Tradr, a prominent innovator in the Exchange-Traded Fund (ETF) market, has today significantly expanded its product suite with the launch of nine new single-stock 2X leveraged ETFs. This marks Tradr's most extensive collection of such launches to date, pushing its total lineup to 48
Investors turned upbeat ahead of Sarepta’s data presentations in Vienna, where the company is expected to share new Duchenne muscular dystrophy results and updates from its broader gene therapy pipeline.
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking place Oct. 7-11, 2025, in Vienna, Austria.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) that were approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in the third quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29, 2025, before market open. This highly anticipated announcement is expected to inject significant volatility into the stock, with analysts
